73
Participants
Start Date
July 12, 2019
Primary Completion Date
November 23, 2021
Study Completion Date
November 23, 2021
Remibrutinib
Remibrutinib 100 mg was administered orally as two 50 mg hard gelatin capsules. Patients in the remibrutinib 100 mg bid dose group took 2 capsules of active medication in the morning and 2 capsules of active medication in the evening. Patients in the remibrutinib 100 mg qd dose group took 2 capsules of active medication in the morning and 2 capsules of the placebo in the evening.
Placebo
Placebo was administered orally as two hard gelatin capsules. Patients in the placebo dose group took 2 capsules of placebo in the morning and 2 capsules of placebo in the evening.
Novartis Investigative Site, Lausanne
Novartis Investigative Site, Sofia
Novartis Investigative Site, Glostrup Municipality
Novartis Investigative Site, Clayton
Novartis Investigative Site, Basel
Novartis Investigative Site, Debrecen
Novartis Investigative Site, Woodville
Novartis Investigative Site, Hobart
Novartis Investigative Site, Ghent
Novartis Investigative Site, Berlin
Novartis Investigative Site, Madrid
Novartis Investigative Site, Vigo
Novartis Investigative Site, Taichung
Novartis Investigative Site, Taichung
Novartis Investigative Site, Taichung
Novartis Investigative Site, Valencia
Novartis Investigative Site, Kaohsiung City
Novartis Investigative Site, Nanjing
Novartis Investigative Site, Hefei
Novartis Investigative Site, Chengdu
Novartis Investigative Site, Boston
Novartis Investigative Site, Sabadell
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Liverpool
Novartis Investigative Site, Swindon
Novartis Investigative Site, Tyne and Wear
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY